EVOTEC ANNOUNCES Q1 2006 FINANCIAL RESULTS
Evotec revenues for the first quarter 2006 increased by 12% to EUR 17.8 million (2005: EUR 15.9 million). Growth was mainly driven by the strong Q1 performance in the Services Division. Revenues in our Services Division increased by 14% to EUR 15.4 million (2005: EUR 13.6 million). In Discovery Services, the achievement of the milestone with Boehringer Ingelheim and, in Chemical and Pharmaceutical Development, mainly the strong sales performance in Pilot Plant as well as Formulation Services were the main contributors.
Oxfordshire Bioscience (http://www.oxfordshirebioscience.com/obn_/news.php?p=news_.tem&r=ULEOX6NRAB4295)